Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences (KZR) is a clinical-stage biotechnology company pioneering novel small molecule therapeutics for autoimmune disorders and oncology. This page provides authoritative updates on corporate developments, clinical research, and strategic initiatives essential for informed decision-making.
Access real-time updates on KZR-616 clinical trials, regulatory milestones, and scientific advancements alongside financial disclosures and partnership announcements. Our curated news collection serves investors, researchers, and healthcare professionals seeking comprehensive insights into the company’s progress.
Key coverage areas include immunoproteasome inhibitor developments, trial phase updates, intellectual property news, and collaborative research efforts. All content undergoes rigorous verification to ensure alignment with SEC filings and peer-reviewed publications.
Bookmark this page for streamlined access to KZR’s latest material events. Combine our news monitoring with SEC filings and medical journals for complete due diligence.
Kezar Life Sciences, a clinical-stage biotechnology company (NASDAQ: KZR), announced the grant of nonqualified stock options to six employees, totaling 232,000 shares at an exercise price of
Kezar Life Sciences reported a net loss of $68.2 million for 2022, compared to $54.6 million in 2021, and a Q4 net loss of $18.2 million. Cash and equivalents stood at $276.6 million as of December 31, 2022, up from $208.4 million in 2021. The company is advancing its zotomipzomib program with the initiation of the PALIZADE Phase 2b trial in lupus nephritis and the PORTOLA trial in autoimmune hepatitis, both set to begin in 2023. Additionally, the KZR-261 Phase 1 trial is currently enrolling its sixth cohort. The increase in research and development expenses reflects investments in these clinical programs, with total R&D costs rising to $51 million in 2022.
Kezar Life Sciences, Inc. (NASDAQ: KZR) has announced the rescheduling of its virtual Research and Development Day to March 15, 2023, at 4:30 PM ET. The event aims to set expectations for 2023 and provide updates on its clinical assets, particularly the advancement of the PALIZADE study for zetomipzomib in lupus nephritis. Additionally, Dr. Craig S. Lammert will discuss autoimmune hepatitis, emphasizing the unmet treatment needs. Following the presentation, a Q&A session will be held. Zetomipzomib is noted for its potential in treating autoimmune disorders without causing immunosuppression.
Kezar Life Sciences (Nasdaq: KZR) has announced a virtual Research and Development Day on March 22, 2023, at 4:30 PM ET. The event will detail the company's pipeline, focusing on zetomipzomib and its development in lupus nephritis, as well as the recently initiated PORTOLA study for autoimmune hepatitis. Key presentations will include insights from experts, such as Craig S. Lammert, M.D. Zetomipzomib, primarily aimed at autoimmune diseases, demonstrated favorable safety in trials. The event will also discuss KZR-261, a novel cancer treatment targeting the protein secretion pathway. Interested parties can register through Kezar's website.
Kezar Life Sciences, a clinical-stage biopharmaceutical company, announced the grant of nonqualified stock options to three employees to purchase a total of 33,000 shares at an exercise price of $5.43 per share, equivalent to the closing price on March 2, 2023. The options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly. This grant is part of the company's 2022 Inducement Plan and aims to attract new talent. Kezar is known for its innovative treatments for immune-mediated and oncologic disorders, including its lead asset, Zetomipzomib, currently in Phase 2 trials.
